Aeterna Zentaris Reports Second Quarter 2018 Financial and Operating Results
Aeterna Zentaris Inc. (AEZS)
Last aeterna zentaris inc. earnings: 11/7 06:28 pm
Check Earnings Report
US:NASDAQ Investor Relations:
zentaris.com
Company Research
Source: GlobeNewswire
CHARLESTON, S.C., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), a biopharmaceutical company engaged in developing and commercializing pharmaceutical products, today reported financial and operating results for the second quarter ended June 30, 2018. All Amounts are in U.S. Dollars Recent Key Developments The Company’s U.S. and Canadian out-licensing partner, Strongbridge Biopharma plc (NASDAQ: SBBP) officially launched our product Macrilen™ (macimorelin) in the United States effective July 23, 2018. Macrilen™ is the first and only FDA-approved oral ghrelin receptor agonist to be administered in the diagnosis of patients with adult growth hormone deficiency (AGHD) in the United States.The Company successfully submitted its required response to the European Medicines Agency (EMA) for the use of macimorelin for the evaluation of AGHD in July 2018.The Company continues to respond to out-licensing and other commercial partners for other markets gl
Show less
Read more
Impact Snapshot
Event Time:
AEZS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AEZS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AEZS alerts
High impacting Aeterna Zentaris Inc. news events
Weekly update
A roundup of the hottest topics
AEZS
News
- Aeterna Zentaris Inc. (NASDAQ: AEZS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Aeterna Zentaris Inc. (NASDAQ: AEZS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Aeterna Zentaris Inc. (NASDAQ: AEZS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ceapro Receives Final Court Approval for Merger with Aeterna ZentarisGlobeNewswire
- Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone DeficiencyGlobeNewswire
AEZS
Sec Filings
- 3/28/24 - Form 6-K
- 3/27/24 - Form 20-F
- 3/27/24 - Form 6-K
- AEZS's page on the SEC website